FDA: Don’t use certain prenatal tests to diagnose genetic abnormalities
Health care providers should not use non-invasive prenatal screening tests alone to diagnose genetic abnormalities due to the potential for false results, the Food and Drug Administration warned last week. Also known as cell-free DNA tests or non-invasive prenatal tests, these laboratory developed tests in most cases are not reviewed by the FDA.
“Patients and health care providers should be aware of the risks and limitations of using these genetic prenatal screening tests and that they should not be used alone to diagnose chromosomal (genetic) abnormalities,” FDA said, citing reports that some patients and providers have made critical health care decisions based on the results without additional confirmatory testing.
Related News Articles
Headline
Wendy Kim, DNP, R.N., vice president and chief nursing officer of Henry Ford Health in Michigan, shares how the system’s virtual nursing program is reducing…
Headline
The Food and Drug Administration has identified a recall by Cook Medical of Zenith Alpha 2 Thoracic Endovascular Graft proximal components after Cook Medical…
Headline
Joy A. Rhoden, AHA senior vice president and executive director of health outcomes and care transformation, shares the AHA’s top strategic…
Headline
The Centers for Disease Control and Prevention announced Dec. 16 that it adopted individual-based decision-making for parents deciding whether to give the…
Headline
The Centers for Disease Control and Prevention issued an advisory Dec. 3 on an outbreak of Marburg virus in Ethiopia. The agency said a risk of spread to the U…
Headline
The AHA Dec. 4 released a new resource outlining how hospitals and health systems can take action to improve care for people with disabilities. Solutions were…